

Press Release Archives**March 3, 2000****Change in Market Timing for Capital Market Segment due to Sun Outage**

The Department of Telecommunications (DoT) has informed the Exchange that there would be sun-outage from March 6, 2000 till March 17, 2000 between 1100 hours and 1130 hours. Due to this Trading Members may face loss of connectivity during this period.

The Exchange has decided to change the market timing as follows:

Normal Market open : 1000 hours

Normal Market will remain close : 1100 hours to 1130 hours

Normal Market re-open : 1135 hours after a pre-open of five minutes

Normal Market close : 1600 hours

The change in market timings shall be effective from March 6, 2000 till March 17, 2000.

[Top](#)

Given below are names of corporates with maximum number of complaints pending

Given below are names of corporates with maximum number of complaints pending against them for more than 2 months as on February 29, 2000.

Sr. No	Name of Corporate	Number of complaints pending
1	Motorol (I) Limited	37
2	Vatsa Corporation Limited	37
3	Xedd Telecom Limited	33
4	Patheja Forgings & Auto Parts Manufacturers Limited	14
5	Grapco Industries Limited	9
6	Satyam Computer Services Limited	8
7	Padmini Polymers Limited	6
8	Prudential Capital Markets Limited	6
9	Pittie Cement Limited	5
10	RS Software Limited	4

[Top](#)

Press reports regarding Ranbaxy Laboratories Ltd.

The press today had reports on Ranbaxy Laboratories Ltd. considering international acquisitions.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.

Ranbaxy Laboratories Limited has vide their letter dated March 3, 2000 stated "We wish to clarify the factual position on the contents of the above news item in so far as it relates to Ranbaxy Laboratories Ltd. (Ranbaxy) for information of investing publics, as follows :

- 1.Ranbaxy has retained the services of M/s. Warburg Dillion Read,, an international investment bank for looking for acquisition opportunities in USA and in Europe.
- 2.Ranbaxy has not issued any mandate nor retained the services of Rabobank for any acquisitions etc. overseas.
- 3.Ranbaxy is currently examining the possibility of acquiring M/s. Sidmak Laboratories Inc., of USA (Sidmak); the net sales of Sidmak for the year ended December 31' 99 is reported to be approximately US\$87 million.
- 4.While investment banks bring opportunities of possible acquisitions in the normal course of their business from time to time to Ranbaxy, there is nothing specific or concrete that we can say in this regard as of now.
- 5.There has never been any proposal for acquiring American Generics Inc., (American Generics); however, Ranbaxy Pharmaceuticals Inc., USA (RPI) (a wholly owned step-down subsidiary of Ranbaxy) has entered into an MOU in late February this year for acquiring a branded product group from American Generics for which the customary due diligence exercises and definitive agreements etc. are yet to be completed/executed.
6. Ranbaxy is neither pursuing nor it has presently any plans to acquire any stakes in Schein Pharmaceuticals Inc., USA."

[Top](#)